O'Dell Group’s Castle Biosciences CSTL Stock Holding History

O'Dell Group’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,041	Closed	-$44K	–	169
2023 Q4	$44K	Buy	+2,041	New	+$35.9K	0.01%	217

Other funds holding CSTL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

O'Dell Group's CSTL Position: Q1 2024 in Review

O'Dell Group sold out of Castle Biosciences (CSTL) in Q1 2024, closing a stake of 2,041 shares — an estimated $44K sold.

O'Dell Group first reported a position in CSTL in Q4 2023 and held it in 1 quarter. The position peaked at $44K in Q4 2023. 151 funds tracked by Wall St. Rank hold CSTL as of Q1 2024.

O'Dell Group reported no remaining Castle Biosciences position as of Q1 2024 after selling out during the quarter.
O'Dell Group sold 2,041 Castle Biosciences shares in Q1 2024, an estimated $44K.
O'Dell Group first reported a position in Castle Biosciences in Q4 2023 and held it in 1 quarter.
O'Dell Group's Castle Biosciences position peaked at $44K in Q4 2023.
151 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2024.

Based on O'Dell Group's 13F filing for Q1 2024, filed 7 May 2024.